Biogen Idec Will Move MS Therapy Into Phase III After Fumapharm Buy
This article was originally published in The Pink Sheet Daily
Acquisition follows the release of positive Phase II study results of BG-12 in relapsing-remitting MS.
You may also be interested in...
We’ve got this year’s winners for the Deals Of The Year, as well as this week’s deal news from Forest/Aptalis, Royalty Pharma, Biogen Idec/Sangamo and a string of early deals from Johnson & Johnson.
Paying cash up front to scientists, hospitals, biotechs and pharmas in exchange for their royalty stakes in successful drugs has proven profitable for Royalty Pharma. The firm has begun applying its long-term strategy to late-stage clinical candidates in addition to marketed products.
Company is “open for business” on deals, Mullen says during break at Massachusetts Biotechnology Council investor conference.